Akèy › Kansè tete negatif triple › Florid › Tampa
Etid klinik pou Kansè tete negatif triple nan Tampa, FL
15 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Tampa (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Moffitt Cancer Center, Tampa
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Ap rekriteFaz 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Moffitt Cancer Center and Research Institute, Tampa
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
- Moffitt Cancer Center, Tampa
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
Ap rekriteFaz 1 bonè
- Moffitt Cancer Center, Tampa
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Tampa
- Kansè Poumon ki pa ti selil51 etid
- Kansè nan tete43 etid
- Kansè (tout kalite)39 etid
- Kansè kolorektal34 etid
- Leksemi mieloïd egi29 etid
- Kansè Metastatik29 etid
- Kansè poumon29 etid
- Kansè pankreyas26 etid
- Kansè ovè21 etid
- Melanom19 etid
- Sendwòm myelodisplastik19 etid
- Kansè pwostat18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.